Thanks Peter. OMER tends to be involved in some fairly unique projects between this PDE10 inhibitor, unlocking the orphan GPCRs, and the MASP-2 program (http://www.omeros.com/pipeline/masp2.htm ). I just don't tend to think much of their lead drugs for surgery that are effectively reformulations of generic drugs (http://www.omeros.com/pipeline/pharma.htm ). I may take a much closer look at OMER after Phase 3 results are out for these drugs, with my interest increasing if these were to fail and the stock to take a hit.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.